Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin

Inclusion Criteria: * Healthy male subjects aged 20 - 45 years. * A body weight in the range of 50 kg (inclusive) - 90 kg (exclusive) and a body mass index (BMI) in the range 18.5 kg/m2 (inclusive) - 27 kg/m2 (inclusive). * Sufficient ability to understand the nature of the study and any hazards of participating in it. Provide written informed consent after being fully. informed about the study procedures. Exclusion Criteria: * Presence or history of hypersensitivity or allergic reactions to drugs including investigational product (clopidogrel, digoxin or aspirin) * Clinically relevant abnormal medical history that could interfere with the objectives of the study. * A subject with history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug. * A subject whose lab test results are as follows; Platelet count or PT, aPTT \< 0.9 x lower limit of reference range of \> 1.1 x upper limit of reference range. * A subject whose SBP is over 160 mmHg or below 90 mmHg and DBP is over 100 mmHg or below 50 mmHg. * Clinically significant abnormal findings of ECG during screening test. * Presence or history of drug abuse or positive result in urine drug screening test. * Participation in other clinical trial within 2 months before first dose. * Use of CYP inducer (ex. rifampin) within 4 weeks before first dose. * Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter medication or vitamin substances within 1 week before first dose. * Use of grapefruit juice within 1 week before first dose. * Blood donation during 2 months or apheresis during 1 month before the study. * Use of alcohol over 21 units/weeks * Smoking of more than 10 cigarettes/days within 3 months before first dose. * Subject judged not eligible for study participation by investigator.